A safety-first practitioner guide to UK REVOLAX packaging, non-UK products, provenance, conformity and traceability.
When an injectable product is going into a patient, recognising the brand name on the box is not enough. UK aesthetic practitioners need to know what they are purchasing, which market the product was intended for, who supplied it, where it came from and whether it can be traced.
The three real packaging examples in this guide illustrate that difference. The REVOLAX shown in Image 1 is the UK/IE-market presentation. The REVOLAX products shown in Images 2 and 3 are not intended for the UK market and should not be used in the UK.
Patient safety is paramount.
Browse the REVOLAX range at Longeva Pharma →
Which REVOLAX Packaging Is for the UK Market?
Image 1 — UK & Ireland REVOLAX Packaging
✓ UK/IE-MARKET PACKAGING
Figure 1: REVOLAX Deep packaging for the UK & Ireland market.
From 4 April 2024, ACROSS Co., Ltd., the manufacturer of REVOLAX, introduced revised packaging for REVOLAX products intended for the UK and Ireland distribution channel. The UK/IE presentation incorporates a distinctive black lower section together with UK & Ireland identification. The published packaging announcement says the redesign followed concerns about counterfeit and parallel-imported REVOLAX and was intended to help practitioners distinguish product intended for the UK/IE market.
The announcement also states that this was a packaging change rather than a reformulation: the product remained the same CE-marked REVOLAX product. Read the packaging announcement.
Shop REVOLAX Deep at Longeva Pharma →
Which REVOLAX Packaging Should Not Be Used in the UK?
Image 2 — Non-UK REVOLAX Packaging
✕ NOT FOR UK USE
Figure 2: REVOLAX Deep packaging not intended for the UK market.
Notice the wording printed on this box: “Not intended for sale in EU.” For UK practitioners, however, the important point for this product is not simply the EU wording.
This product is not intended for the UK market and should not be used in the UK.
A familiar REVOLAX logo should never override questions about a product's intended market and supply chain.
Another REVOLAX Pack That Is Not for UK Use
Image 3 — Alternative Non-UK REVOLAX Packaging
✕ NOT FOR UK USE
Figure 3: Another REVOLAX Deep presentation not intended for the UK market.
This product is not intended for the UK market and should not be used in the UK. Practitioners should not treat this simply as an alternative design of the UK REVOLAX box. Products intended for different territories may be subject to different regulatory, labelling and distribution arrangements.
Why Does REVOLAX Packaging Matter?
The photographs make the differences visible, but this article is not really about cardboard boxes. It is about patient safety, product provenance and professional accountability.
Before administering an injectable product, a practitioner should have confidence in its identity, manufacturer, intended market, supplier, applicable conformity information, batch or lot number, expiry date, packaging integrity, provenance and traceability.
Can I account for the product I am about to put into my patient's body?
Genuine REVOLAX Does Not Automatically Mean REVOLAX Intended for the UK
Authenticity matters, but it is not the only consideration. A product may potentially originate from the genuine manufacturer while having been intended for another territory. UK practitioners therefore need to consider two different questions: Is the product authentic? and Is this product intended and appropriately supplied for the market in which I practise?
For the examples in this article: Image 1 — UK/IE-market REVOLAX. Image 2 — not intended for the UK market; do not use in the UK. Image 3 — not intended for the UK market; do not use in the UK.
Does Non-UK REVOLAX Automatically Mean Counterfeit?
No. A product intended for another market should not automatically be labelled counterfeit solely because its packaging differs from the UK presentation. Likewise, parallel importation and counterfeiting are not the same thing. The 2024 REVOLAX packaging announcement discusses counterfeit and parallel-imported products as separate concerns.
This distinction does not change the practical advice concerning the two non-UK examples illustrated here: they should not be used in the UK.
Patient Safety Must Come Before Price
An aesthetic clinic is also a business, but price cannot be the deciding factor when there are unresolved questions about an injectable product's provenance or intended market. Ask where the product came from, who supplied it, which market it was intended for, whether its batch can be traced and whether its integrity has been maintained through the supply chain.
Patient safety must come first.
What Are the Medical Device Rules in Great Britain?
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates the UK medical devices market. For these regulatory purposes, Great Britain means England, Scotland and Wales; different medical-device rules apply in Northern Ireland.
Current MHRA guidance states that medical devices need to be registered with the MHRA before being placed on the Great Britain market, subject to the applicable requirements. Manufacturers also need to comply with relevant product-marking and conformity-assessment requirements. Importers and distributors have relevant responsibilities, including obligations concerning storage, transportation and checking device labels for CE or UKCA marking. Read MHRA guidance on regulating medical devices in the UK.
Is CE Marking Still Accepted in Great Britain?
Yes. Qualifying CE-marked medical devices continue to be accepted in Great Britain under transitional arrangements. Under current guidance, qualifying general medical devices compliant with the former EU Medical Devices Directive or AIMDD can be placed on the GB market until the sooner of certificate expiry or 30 June 2028, while qualifying general medical devices compliant with the EU Medical Devices Regulation can currently be placed on the GB market until 30 June 2030, subject to the applicable conditions.
The UKCA route also remains available. A conformity mark, however, is only one element of responsible procurement. Practitioners should consider the whole picture: conformity + manufacturer + intended market + supplier + batch + expiry + provenance + traceability.
10 Checks Before Buying REVOLAX in the UK
- Check the intended market. Is the product intended for the UK market?
- Look at the packaging. Know what the current UK/IE presentation looks like.
- Know your supplier. Know the legal entity supplying the product.
- Check conformity information. Review the applicable regulatory and conformity information.
- Check the manufacturer. Manufacturer information should be identifiable and consistent.
- Check the batch or lot number. Record it within your clinical governance system.
- Check the expiry date. Do not use a product with missing, altered or suspicious expiry information.
- Check packaging integrity. Look for evidence of damage or interference.
- Consider storage and transportation. Supply-chain integrity matters.
- Never put price ahead of patient safety.
REVOLAX UK vs Non-UK Packaging: Quick Practitioner Reference
✓ IMAGE 1 — UK/IE-MARKET REVOLAX
✕ IMAGE 2 — NOT FOR UK USE
✕ IMAGE 3 — NOT FOR UK USE
What Should You Do If You Are Offered Images 2 or 3?
For UK clinical use, the advice is straightforward: do not use them. Source REVOLAX intended for the UK market through an appropriate professional supply chain instead. Do not allow a lower price or reassurance that a product is “genuine” to override the fact that it is not intended for the UK market.
Why Batch Traceability Matters After Treatment
Procurement does not stop mattering when the box is opened. If a manufacturer, supplier or regulator subsequently identifies an issue involving a particular batch, you should be able to establish which batch you received, who supplied it, when you received it and which patients received it.
SUPPLIER → PRODUCT → BATCH → PRACTITIONER → PATIENT
The Practitioner Safety Rule
Before administering an injectable product, understand what it is, who manufactured it, where it came from, which market it was intended for, who supplied it, which batch you have, when it expires and how it can be traced.
If those fundamentals cannot be established confidently, the product should not reach the treatment tray.
Patient safety is paramount.
Shop the REVOLAX Range at Longeva Pharma
UK practitioners can browse the REVOLAX range at Longeva Pharma, including REVOLAX Fine and REVOLAX Deep. You can also browse Longeva's wider professional dermal filler collection.
REVOLAX Packaging FAQs
Which REVOLAX packaging is intended for the UK?
The UK/IE presentation introduced from April 2024 includes the distinctive black lower section and UK & Ireland identification illustrated in Image 1.
Can I use the REVOLAX shown in Images 2 and 3 in the UK?
No. The products illustrated in Images 2 and 3 are not intended for the UK market and should not be used in the UK.
What if non-UK REVOLAX is genuine?
Authenticity and intended market are different questions. The advice concerning the examples shown here remains the same: Images 2 and 3 should not be used in the UK.
Are Images 2 and 3 counterfeit?
The photographs alone do not establish that. The important point for UK practitioners is that these products are not intended for the UK market and should not be used in the UK.
Why did the UK REVOLAX box change?
The published announcement says the change followed concerns involving counterfeit and parallel-imported REVOLAX and was intended to help practitioners identify and trace REVOLAX intended for the UK/IE market.
Did the REVOLAX formulation change with the new packaging?
The UK/IE packaging announcement describes it as the same CE-marked product with new packaging.
Is CE marking still accepted for medical devices in Great Britain?
Yes. Qualifying CE-marked medical devices continue to be recognised under applicable transitional arrangements; the precise timeline depends on the device and regulatory route.
Does a CE mark prove REVOLAX is genuine?
No. Conformity marking is one element of product verification. Practitioners should also consider manufacturer information, intended market, supplier, batch, expiry, provenance and traceability.
Is parallel-imported REVOLAX the same as counterfeit REVOLAX?
No. They are different concepts.
The Bottom Line
Image 1: ✓ UK/IE-market REVOLAX.
Image 2: ✕ Not intended for the UK market — DO NOT USE IN THE UK.
Image 3: ✕ Not intended for the UK market — DO NOT USE IN THE UK.
Know the product. Know the intended market. Know the supplier. Check conformity information. Check the batch. Check the expiry. Establish provenance. Maintain traceability.
Because this is not ultimately about which box looks different. It is about what you are putting into your patient's body. Patient safety is paramount.
Related Longeva Pharma practitioner resources
Explore Toxins and Diluents; Longeva Pharma on Faces; Greater Manchester same-day toxin supply; toxin product and service directory; Faces Consent practitioner guide; practitioner account registration. Prescription-only medicines require appropriate verification, prescribing and dispensing; same-day availability depends on location, timing and stock.